Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
C4 Therapeutics said it will present new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 relapsed/refractory multiple myeloma trial at the 23rd IMS Annual Meeting.
C4 Therapeutics said it will present new biomarker data on cemsidomide’s immunomodulatory effects with dexamethasone from its Phase 1 relapsed/refractory multiple myeloma trial at IMS.